UBS initiated coverage on Altimmune with a new price target
$ALT
Biotechnology: Pharmaceutical Preparations
Health Care
UBS initiated coverage of Altimmune with a rating of Buy and set a new price target of $26.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/10/2025 | $1.00 | Sell | Goldman |
| 2/28/2025 | Mkt Perform | William Blair | |
| 1/8/2025 | $18.00 | Buy | Stifel |
| 11/12/2024 | $26.00 | Buy | UBS |
| 4/29/2024 | Buy → Neutral | Guggenheim | |
| 1/24/2024 | $13.00 | Neutral | Goldman |
| 3/22/2023 | $20.00 → $6.00 | Buy → Neutral | Goldman |
| 12/1/2022 | $20.00 | Buy | Goldman |
DEF 14A - Altimmune, Inc. (0001326190) (Filer)
10-Q - Altimmune, Inc. (0001326190) (Filer)
8-K - Altimmune, Inc. (0001326190) (Filer)
Appointment recognizes Mr. Durso's extensive commercial expertise as Altimmune prepares for Phase 3 development of pemvidutide in MASH Mitchel Sayare, Ph.D., to remain on the Board as Independent Director GAITHERSBURG, Md., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that its Board of Directors has appointed Jerry Durso as Chairman, effective August 12, 2025. Mr. Durso succeeds Mitchel Sayare, Ph.D., who will continue to serve on the Board as an Independent Director. The leadership transition is part of the Board's
Ms. Lawver, former Chief Commercial Officer of Dexcom and Global Vice President at Johnson & Johnson responsible for billion-dollar Immunology and Cardiovascular & Metabolism Portfolios over her 20-year career Mr. Durso led biopharmaceutical company focused on liver disease as former CEO of Intercept Pharmaceuticals, previously oversaw multiple blockbuster franchises including cardiovascular and diabetes during 22-year tenure at Sanofi GAITHERSBURG, Md., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced the expansion of its Board of Directors with the appointments of Teri Lawver and Jerry Durso. "We are thrilled
GAITHERSBURG, Md., March 27, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced the appointment of Catherine Angell Sohn, Pharm.D. to its Board of Directors. "We are delighted to welcome Catherine to our Board of Directors," said Vipin K. Garg, Ph.D., President and Chief Executive Officer. "Her broad experience in the pharmaceutical industry including strategic product development, business development and commercialization will be invaluable to Altimmune as we pursue our mission to develop next generation peptide therapeutics for obesity and liver disease." Dr. Sohn added, "I am very honored and pleased to join the Altimmun
Pemvidutide is the only drug currently granted Fast Track Designation in AUD RECLAIM, a Phase 2 trial of pemvidutide in AUD, is currently enrolling GAITHERSBURG, Md., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing peptide-based therapeutics for liver and cardiometabolic diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to pemvidutide for the treatment of Alcohol Use Disorder (AUD). Fast Track designation is intended to accelerate the development and review of new drugs that target serious conditions and address unmet medical needs. RECLAIM (NCT06987513)
Positive data from the IMPACT Phase 2b trial reinforces the potential for pemvidutide to be a highly differentiated MASH therapy Pemvidutide is the first product candidate to achieve statistically significant MASH resolution and weight loss at 24 weeks New data from the IMPACT trial demonstrates potentially class-leading improvements in corrected T1 (cT1), an important marker of liver inflammation and fibrosis End-of-Phase 2 Meeting with FDA expected in Q4 2025 Cash, cash equivalents and short-term investments of $183.1 million as of June 30, 2025 Webcast to be held today, August 12, 2025, at 8:30 a.m. ET GAITHERSBURG, Md., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:A
Appointment recognizes Mr. Durso's extensive commercial expertise as Altimmune prepares for Phase 3 development of pemvidutide in MASH Mitchel Sayare, Ph.D., to remain on the Board as Independent Director GAITHERSBURG, Md., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that its Board of Directors has appointed Jerry Durso as Chairman, effective August 12, 2025. Mr. Durso succeeds Mitchel Sayare, Ph.D., who will continue to serve on the Board as an Independent Director. The leadership transition is part of the Board's
4 - Altimmune, Inc. (0001326190) (Issuer)
4 - Altimmune, Inc. (0001326190) (Issuer)
4 - Altimmune, Inc. (0001326190) (Issuer)
Goldman resumed coverage of Altimmune with a rating of Sell and set a new price target of $1.00
William Blair initiated coverage of Altimmune with a rating of Mkt Perform
Stifel initiated coverage of Altimmune with a rating of Buy and set a new price target of $18.00
4 - Altimmune, Inc. (0001326190) (Issuer)
4 - Altimmune, Inc. (0001326190) (Issuer)
SC 13G/A - Altimmune, Inc. (0001326190) (Subject)
SC 13G/A - Altimmune, Inc. (0001326190) (Subject)
SC 13G/A - Altimmune, Inc. (0001326190) (Subject)
Positive data from the IMPACT Phase 2b trial reinforces the potential for pemvidutide to be a highly differentiated MASH therapy Pemvidutide is the first product candidate to achieve statistically significant MASH resolution and weight loss at 24 weeks New data from the IMPACT trial demonstrates potentially class-leading improvements in corrected T1 (cT1), an important marker of liver inflammation and fibrosis End-of-Phase 2 Meeting with FDA expected in Q4 2025 Cash, cash equivalents and short-term investments of $183.1 million as of June 30, 2025 Webcast to be held today, August 12, 2025, at 8:30 a.m. ET GAITHERSBURG, Md., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:A
GAITHERSBURG, Md., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company, today announced that it will report its second quarter 2025 financial results on Tuesday, August 12, 2025. Altimmune management will host a conference call at 8:30 am E.T. on August 12 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune's Investor Relations website at https://ir.altimmune.com/investors. Participants who would like to join the call may register here to receive the dial-in numbers and unique PIN to access the call. Shortly after the call, a replay will be available on the Investor R
First product candidate to demonstrate significant MASH effects and weight loss at 24 weeks Trial met its primary endpoint with statistically significant MASH resolution without worsening of fibrosis in up to 59.1% of participants in an ITT analysis Fibrosis improvement without worsening of MASH in up to 34.5% of participants in an ITT analysis Supplemental AI-based analysis demonstrated statistically significant reductions in liver fibrosis at 24 weeks Weight loss of up to 6.2% at 24 weeks with no plateauing Potentially best-in-class tolerability, with less than 1% treatment discontinuations due to adverse events in pemvidutide-treated participants Conference call to be held on June 2